Yes. Ankylosing spondylitis (AS) causes bone spurs, but they are not the same degenerative spurs seen in osteoarthritis. In AS, chronic inflammation at entheses (tendon and ligament attachment sites) triggers a repair response that lays down new woven bone. Over years, this ossification can bridge vertebral corners, forming syndesmophytes that fuse the spine. Roughly 20-40% of patients develop these bridging spurs within a decade of diagnosis, depending on disease activity and treatment.

The Enthesitis-to-Ossification Mechanism

The spur in AS begins where mechanical stress meets immune attack. Entheses anchor tendons, ligaments, and joint capsules to bone, and they experience concentrated tensile and shear forces daily. In genetically susceptible people, these sites become the target of an inflammatory cascade driven by interleukin-23 (IL-23) and interleukin-17 (IL-17).

The sequence runs in stages. First, resident immune cells release TNF and IL-17, recruiting neutrophils and macrophages to the enthesis. Second, chronic inflammation activates osteoprogenitor cells in the adjacent periosteum and bone marrow. Third, these cells differentiate into osteoblasts under signaling from bone morphogenetic proteins (BMPs) and the Wnt pathway. Fourth, the new osteoblasts deposit woven bone at the enthesis footprint. This is repair, not erosion, and it is the critical distinction from rheumatoid arthritis.

As the woven bone matures, it extends along the outer fibers of the annulus fibrosus at the vertebral rim. What starts as a tiny bony whisker at a single vertebral corner grows into a syndesmophyte, a vertically oriented bridge connecting adjacent vertebrae. When enough of these bridges form, the spine becomes a continuous column of bone. Radiologists call the end-stage appearance a "bamboo spine," a term that describes the fused radiographic silhouette.

A plain-language version: the body responds to years of inflammation at tendon anchors by welding extra bone onto the skeleton, and in the spine those welds connect vertebrae that should move independently.

The same process explains spurs at the heel (Achilles and plantar fascia insertions), the pelvis (iliac crest and ischial tuberosity), and the hip margins. These peripheral spurs are often palpable and can be seen on plain radiographs years before spinal fusion completes.

Quantified Context: How Often and How Fast

Bone spur formation in AS is common but not universal, and the timeline matters for anyone tracking their own imaging.

Radiographic sacroiliitis is the earliest structural change, typically appearing within 3 to 5 years of symptom onset. Syndesmophytes follow later, usually detectable on plain radiographs after 5 to 10 years of active disease, though MRI can show early bone marrow edema years before ossification is visible.

Studies using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) show that spinal radiographic progression averages about 1 to 2 mSASSS points every two years in untreated or conventionally treated patients. The mSASSS scale grades each vertebral corner from 0 (normal) to 3 (complete bridging), so a 1-2 point gain can mean one or two corners progressing a single grade. Progression is nonlinear: patients with existing syndesmophytes at baseline progress faster, and smoking roughly doubles the rate of new bone formation in several cohort analyses.

Peripheral enthesophytes appear in a substantial minority. Heel spurs are among the most common, reported in roughly a quarter to a third of AS patients in imaging series, and they correlate with a history of heel pain. Hip joint space narrowing and marginal osteophytes affect a smaller proportion but carry outsized functional consequences, since hip involvement predicts more disability than spinal fusion alone.

Key thresholds clinicians use: a Bath Ankylosing Spondylitis Radiology Index (BASRI) score of 2 or higher at the hip signals clinically meaningful structural damage; a C-reactive protein (CRP) persistently above the upper reference limit predicts faster radiographic progression; and two or more syndesmophytes at baseline is the strongest single predictor of future bridging.

A counterintuitive detail worth flagging: inflammation and new bone formation are partly decoupled. TNF inhibitors control inflammation and improve symptoms, but multiple trials found they do not reliably slow syndesmophyte formation over 2 to 4 years. Some patients on potent biologics still grow new bridges. This suggests that once the osteoblast program is switched on at an enthesis, it can run partly independent of the inflammatory signals that started it.

Timeline of Structural Change

Stage Typical timing What imaging shows Clinical correlate
Enthesitis (active inflammation) Onset to 2 years MRI: bone marrow edema at entheses; X-ray normal Inflammatory back pain, heel pain
Early sacroiliitis 1-5 years X-ray: joint space blurring; MRI: active inflammation Buttock pain, morning stiffness
First syndesmophytes 5-10 years X-ray: bony whiskers at vertebral corners (mSASSS grade 1-2) Reduced spinal mobility begins
Bridging syndesmophytes 10-15 years X-ray: vertical bone bridges (mSASSS grade 3) Loss of lumbar flexion, chest expansion
Partial fusion ("bamboo spine" evolving) 15-25 years X-ray: multiple contiguous bridges Fixed kyphosis risk, fracture vulnerability
End-stage fusion 20+ years Continuous ossification of spinal ligaments Rigid spine, high fracture risk

Timing varies widely. Some patients never progress past sacroiliitis; others fuse within a decade. Smoking, elevated CRP, baseline syndesmophytes, and male sex are associated with faster progression, but no validated model predicts individual trajectories precisely.

Edge Cases: When Spurs Are Not the Whole Story

Bone spurs in AS do not always mean the disease is "active." A patient can have a completely fused, pain-free spine with normal inflammatory markers. The ossification is a historical record of past inflammation, not a live process. Interpreting a new spur on imaging as proof of uncontrolled disease is a common error.

Spinal fractures are the dangerous edge case. A fused, osteoporotic AS spine behaves like a long bone, and a minor fall can produce a fracture through a syndesmophyte or an ankylosed segment. These fractures are unstable and carry a high risk of spinal cord injury. New neck or back pain after minor trauma in a fused spine warrants urgent imaging, not a wait-and-see approach.

Hip involvement follows a different trajectory. Hip arthritis in AS can progress to severe joint space loss and require total hip replacement, often earlier than in osteoarthritis. Marginal osteophytes at the hip are part of this process, but the dominant damage is cartilage loss and joint destruction, not bridging bone.

Another edge case: diffuse idiopathic skeletal hyperostosis (DISH) produces flowing spinal bone that looks similar on X-ray but is not AS. DISH typically spares the sacroiliac joints, affects older adults, and is associated with metabolic syndrome rather than HLA-B27. Misreading DISH as late AS changes management entirely.

Misconceptions and How Spurs Differ From Osteoarthritis

The word "spur" covers at least three biologically distinct structures, and conflating them leads to wrong conclusions about cause and treatment.

Feature AS syndesmophyte Osteoarthritis osteophyte DISH flowing ossification
Primary trigger Enthesitis and inflammation Mechanical wear and cartilage loss Metabolic and mechanical factors
Orientation in spine Vertical, bridging vertebral corners Horizontal, at joint margins Flowing, along anterior longitudinal ligament
Sacroiliac joint Involved early Usually spared Spared
Typical age of onset 20-40 years 50+ years 60+ years
HLA-B27 association Strong None None
Response to anti-inflammatory therapy Symptoms improve; bone progression uncertain Symptom relief only Not applicable

The most persistent misconception is that AS spurs are "wear and tear." They are not. Mechanical stress localizes the inflammation, but the driver is immune-mediated enthesitis. Another misconception is that treating inflammation will prevent all fusion. As noted, TNF inhibitors improve symptoms and reduce inflammation on MRI, but their effect on long-term syndesmophyte formation remains uncertain, and trials have not shown consistent prevention of new bone.

A professional caveat: radiographic progression on mSASSS is a research endpoint, not a treatment target. Clinicians treat symptoms, function, and inflammation, not the mSASSS score itself. Chasing a stable X-ray with escalating therapy is not supported by evidence.

Practical Actions and Red-Flag Warnings

Practical steps for someone with AS who is concerned about bone spurs:

Get baseline imaging. A pelvic X-ray and, if needed, MRI of the sacroiliac joints establish where you are on the structural timeline. Repeat spinal imaging only when symptoms change, not on a fixed schedule. Track inflammatory markers with your clinician. Persistently elevated CRP over months is associated with faster structural progression and is worth discussing at each visit. Stop smoking. Smoking is one of the few modifiable factors consistently linked to faster syndesmophyte formation and worse outcomes in AS. Maintain mobility with daily stretching and extension exercises. A fused segment cannot be unfused, but preserving range in adjacent segments reduces compensatory strain. Discuss bone density screening. AS increases fracture risk through both fusion and osteoporosis; dual-energy X-ray absorptiometry (DXA) is reasonable, especially with long-standing disease or steroid exposure.

Red-flag warnings, seek urgent care:

New neck or back pain after even a minor fall or bump, especially with a known fused spine. This can signal an unstable fracture. New neurological symptoms: numbness, weakness, or bowel or bladder changes. Sudden severe pain between the shoulder blades or at the site of a known syndesmophyte. Fever with new focal back pain, which raises concern for infection at a fused segment or a spinal abscess.

Limitations: What the Evidence Cannot Tell You

The biggest limitation is prediction. No tool reliably forecasts which patient will fuse and which will not. The mSASSS is validated for group-level research, not individual prognosis, and inter-reader reliability for early syndesmophytes is modest. A "normal" X-ray today does not guarantee a normal X-ray in five years.

The second limitation is treatment effect on bone. Trials of TNF inhibitors and IL-17 inhibitors show robust control of inflammation and symptoms, but radiographic outcomes over 2 to 4 years have been inconsistent or modest. Longer-term data beyond 5 years are limited, and no therapy is approved specifically to prevent syndesmophyte formation. Patients should not expect a biologic to guarantee an unfused spine.

The third limitation is imaging timing. Plain radiographs miss early ossification; MRI detects inflammation but not the microscopic bone deposition that precedes visible spurs. CT is more sensitive for bone but involves higher radiation and is rarely used for routine monitoring in AS.

Finally, much of the mechanistic detail on BMP and Wnt signaling comes from animal models and small human tissue studies. The broad cascade is well supported, but the precise molecular switches that commit an enthesis to ossify remain under investigation. That gap matters because it is the most likely target for future therapies aimed at stopping fusion rather than just calming inflammation.

What can be concluded with confidence: AS does cause bone spurs, the mechanism runs from enthesitis through osteoblast activation to syndesmophyte bridging, the process is common and time-dependent, and current treatments control inflammation far better than they control ossification.